AIMS/HYPOTHESIS: Uncoupling protein-2 (UCP2) is thought to play a role in insulin secretion and the development of obesity. In this study, we investigated the effects of genetic variation in UCP2 on type 2 diabetes and obesity, as well as on metabolic phenotypes related to these diseases, in Pima Indians. METHODS: The coding and untranslated regions of UCP2, and approximately 1 kb of the 5' upstream region, were sequenced in DNA samples taken from 83 extremely obese Pima Indians who were not first-degree relatives. RESULTS: Five variants were identified: (1) a -866G/A in the 5' upstream region; (2) a G/A in exon 2; (3) a C/T resulting in an Ala55Val substitution in exon 4; and (4, 5) two insertion/deletions (ins/del; 45-bp and 3-bp) in the 3' untranslated region. Among the 83 subjects whose DNA was sequenced, the -866G/A was in complete genotypic concordance with the Ala55Val and the 3-bp ins/del polymorphism. The G/A polymorphism in exon 2 was extremely rare. To capture the common variation in this gene for association analyses, the -866G/A variant (as a representative of Ala55Val and the 3-bp ins/del polymorphism) and the 45-bp ins/del were also genotyped for 864 full-blooded Pima Indians. Neither of these variants was associated with type 2 diabetes or body mass index. However, in a subgroup of 185 subjects who had undergone detailed metabolic measurements, these variants were associated with 24-h energy expenditure as measured in a human metabolic chamber (p=0.007 for the 45-bp ins/del and p=0.03 for the -866G/A after adjusting for age, sex, family membership, fat-free mass and fat mass). CONCLUSIONS/ INTERPRETATION: Our data indicate that variation in UCP2 may play a role in energy metabolism, but this gene does not contribute significantly to the aetiology of type 2 diabetes and/or obesity in Pima Indians.
AIMS/HYPOTHESIS: Uncoupling protein-2 (UCP2) is thought to play a role in insulin secretion and the development of obesity. In this study, we investigated the effects of genetic variation in UCP2 on type 2 diabetes and obesity, as well as on metabolic phenotypes related to these diseases, in Pima Indians. METHODS: The coding and untranslated regions of UCP2, and approximately 1 kb of the 5' upstream region, were sequenced in DNA samples taken from 83 extremely obese Pima Indians who were not first-degree relatives. RESULTS: Five variants were identified: (1) a -866G/A in the 5' upstream region; (2) a G/A in exon 2; (3) a C/T resulting in an Ala55Val substitution in exon 4; and (4, 5) two insertion/deletions (ins/del; 45-bp and 3-bp) in the 3' untranslated region. Among the 83 subjects whose DNA was sequenced, the -866G/A was in complete genotypic concordance with the Ala55Val and the 3-bp ins/del polymorphism. The G/A polymorphism in exon 2 was extremely rare. To capture the common variation in this gene for association analyses, the -866G/A variant (as a representative of Ala55Val and the 3-bp ins/del polymorphism) and the 45-bp ins/del were also genotyped for 864 full-blooded Pima Indians. Neither of these variants was associated with type 2 diabetes or body mass index. However, in a subgroup of 185 subjects who had undergone detailed metabolic measurements, these variants were associated with 24-h energy expenditure as measured in a human metabolic chamber (p=0.007 for the 45-bp ins/del and p=0.03 for the -866G/A after adjusting for age, sex, family membership, fat-free mass and fat mass). CONCLUSIONS/ INTERPRETATION: Our data indicate that variation in UCP2 may play a role in energy metabolism, but this gene does not contribute significantly to the aetiology of type 2 diabetes and/or obesity in Pima Indians.
Authors: C Y Zhang; G Baffy; P Perret; S Krauss; O Peroni; D Grujic; T Hagen; A J Vidal-Puig; O Boss; Y B Kim; X X Zheng; M B Wheeler; G I Shulman; C B Chan; B B Lowell Journal: Cell Date: 2001-06-15 Impact factor: 41.582
Authors: K Walder; R A Norman; R L Hanson; P Schrauwen; M Neverova; C P Jenkinson; J Easlick; C H Warden; C Pecqueur; S Raimbault; D Ricquier; M H Silver; A R Shuldiner; G Solanes; B B Lowell; W K Chung; R L Leibel; R Pratley; E Ravussin Journal: Hum Mol Genet Date: 1998-09 Impact factor: 6.150
Authors: Franz Krempler; Harald Esterbauer; Raimund Weitgasser; Christoph Ebenbichler; Josef R Patsch; Karl Miller; Mingqiang Xie; Veronika Linnemayr; Hannes Oberkofler; Wolfgang Patsch Journal: Diabetes Date: 2002-11 Impact factor: 9.461
Authors: H Esterbauer; C Schneitler; H Oberkofler; C Ebenbichler; B Paulweber; F Sandhofer; G Ladurner; E Hell; A D Strosberg; J R Patsch; F Krempler; W Patsch Journal: Nat Genet Date: 2001-06 Impact factor: 38.330
Authors: L J Baier; P A Permana; X Yang; R E Pratley; R L Hanson; G Q Shen; D Mott; W C Knowler; N J Cox; Y Horikawa; N Oda; G I Bell; C Bogardus Journal: J Clin Invest Date: 2000-10 Impact factor: 14.808
Authors: Hua Wang; Winston S Chu; Tong Lu; Sandra J Hasstedt; Philip A Kern; Steven C Elbein Journal: Am J Physiol Endocrinol Metab Date: 2003-08-12 Impact factor: 4.310
Authors: Louise T Dalgaard; Gitte Andersen; Lesli H Larsen; Thorkild I A Sørensen; Teis Andersen; Thomas Drivsholm; Knut Borch-Johnsen; Jan Fleckner; Torben Hansen; Nanni Din; Oluf Pedersen Journal: Obes Res Date: 2003-11
Authors: Neena Srivastava; Jai Prakash; Ram Lakhan; C G Agarwal; D C Pant; Balraj Mittal Journal: Mol Cell Biochem Date: 2009-11-12 Impact factor: 3.396
Authors: Adam Mitchell; Faith Pangilinan; Julie Van der Meer; Anne M Molloy; James Troendle; Mary Conley; Peadar N Kirke; John M Scott; Lawrence C Brody; James L Mills Journal: Birth Defects Res A Clin Mol Teratol Date: 2009-02
Authors: Suzette J Bielinski; James S Pankow; Eric Boerwinkle; Molly S Bray; W H Linda Kao; Aaron R Folsom Journal: Acta Diabetol Date: 2008-05-22 Impact factor: 4.280
Authors: P W Franks; K A Jablonski; L M Delahanty; J B McAteer; S E Kahn; W C Knowler; J C Florez Journal: Diabetologia Date: 2008-10-07 Impact factor: 10.122
Authors: Titta Salopuro; Leena Pulkkinen; Jaana Lindström; Marjukka Kolehmainen; Anna-Maija Tolppanen; Johan G Eriksson; Timo T Valle; Sirkka Aunola; Pirjo Ilanne-Parikka; Sirkka Keinänen-Kiukaanniemi; Jaakko Tuomilehto; Markku Laakso; Matti Uusitupa Journal: BMC Med Genet Date: 2009-09-21 Impact factor: 2.103